Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells $400,000.00 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider owned 119,763 shares of the company’s stock, valued at $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The shares were sold at an average price of $27.30, for a total value of $142,560.60.

Urogen Pharma Stock Down 2.1%

Shares of URGN stock traded down $0.85 during mid-day trading on Friday, hitting $39.38. 612,217 shares of the stock were exchanged, compared to its average volume of 787,994. Urogen Pharma has a 52-week low of $13.79 and a 52-week high of $40.35. The firm has a fifty day moving average of $30.98 and a 200 day moving average of $24.33. The company has a market cap of $1.92 billion, a PE ratio of -14.27 and a beta of 1.56.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million. Equities analysts predict that Urogen Pharma will post -0.88 EPS for the current year.

Analysts Set New Price Targets

URGN has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. HC Wainwright reiterated a “buy” rating on shares of Urogen Pharma in a report on Thursday. LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 target price on the stock. Finally, UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Urogen Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $39.50.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in shares of Urogen Pharma by 36.9% during the third quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company’s stock worth $10,664,000 after acquiring an additional 144,181 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Urogen Pharma by 148.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 161,924 shares of the company’s stock worth $3,792,000 after purchasing an additional 96,741 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Urogen Pharma by 19.0% in the fourth quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock valued at $32,264,000 after acquiring an additional 220,264 shares in the last quarter. Rice Hall James & Associates LLC grew its holdings in shares of Urogen Pharma by 8.8% during the fourth quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock worth $6,602,000 after buying an additional 22,733 shares in the last quarter. Finally, Elmind Capital LP acquired a new position in shares of Urogen Pharma in the fourth quarter valued at approximately $2,342,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.